[18F]-Fluorodeoxyglucose Positron Emission Tomography for In Vivo Assessment of Glucose Metabolism in Pheochromoctyoma and Paraganglioma - GLUMEPP

niversitair Medisch Centrum Sint Radboud0 个研究点目标入组 25 人开始时间: 待定最近更新: 2024年4月23日

适应症

试验速览

暂无简介。

•- Age >= 18 years, no upper limit
•- Suspected diagnosis of benign PCC or PGL:
•1. Biochemically proven by elevated plasma and/or urinary (nor)metanephrines
•2. Anatomically substrate; localization of an (extra)-adrenal tumor by conventional anatomical (MRI/CT) imaging
•- Regardless of the genetic status (sporadic or hereditary)
•- Planned for surgical resection (adrenalectomy or extra-adrenal tumor resection)
•- Size tumor at least 1 cm in smallest diameter (as determined by conventional imaging)

•- Malignant PPGL, i.e. presence of lesions on imaging studies suggestive of distant metastasis
•- No initial CT or MRI available
•- Contra-indication for surgery:
•o Based on (biological) age, cardiovascular risk factors, performance status or other co-morbidity as decided by a multidisciplinary team including medical endocrinologist, urologists, radiologists, pathologists and nuclear medicine physicians.
•- Contra-indication for dynamic FDG-PET/CT
•o Diabetes mellitus or fasted glucose level >= 8.0 mmol.L-1
•o Pregnancy
•o Breast-feeding
•o Sever claustrophobia
•- Interval between dynamic FDG-PET/CT and surgery more than 60 days
•- Incapability to adhere to study protocol
•- Inability to give informed consent (e.g. psychiatric illness)

发起方

niversitair Medisch Centrum Sint Radboud